Gritstone Bio, INC

Gritstone Bio, currently undergoing Chapter 11 bankruptcy, has filed its monthly operating report (MOR) for December 2024 with the U.S. Bankruptcy Court for the District of Delaware.

Gritstone Bio has finalized the sale of substantially all of its assets to Seattle Project Corp. for $21.25 million in cash, concluding its Chapter 11 bankruptcy proceedings.

Gritstone Bio has reached agreements to sell its assets for approximately $21.25 million in cash, plus credit bids, following a bankruptcy auction.

Gritstone Bio has filed its monthly operating report for October 2024, detailing its financial status while under Chapter 11 bankruptcy protection.

Gritstone Bio has entered into a debtor-in-possession financing agreement for up to $25 million to support operations during its Chapter 11 bankruptcy.

Gritstone Bio is reducing its workforce by approximately 19% and will be delisted from the Nasdaq stock market following its Chapter 11 bankruptcy filing.

Gritstone Bio's Q2 2024 results reveal ongoing operating losses and a need for additional capital, raising concerns about the company's ability to continue as a going concern.

Gritstone Bio's Q1 2024 results show a net loss of $40.4 million and highlight substantial doubt about the company's ability to continue as a going concern despite a recent $32.5 million capital raise.

Gritstone Bio's 10-K filing highlights its focus on developing next-generation vaccines for cancer and infectious diseases, while also detailing its financial position and future strategies.